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Abstract
Background: Congenital myasthenic syndromes (CMSs) occur as a result of genetic mutations that cause aberrations
in structure and/or function of proteins involved in neuromuscular transmission. Acetylcholine receptor epsilon (ε)
subunit (CHRNE) gene mutations account for about 30–50 % of genetically diagnosed cases. We report a rare CHRNE
gene mutation in a South Asian female with CMS.
Case presentation: A 17-year-old Maldivian female presented with bilateral partial ptosis, fatigable proximal
muscle weakness and slurring of speech noted since the age of 2 years. She could not run, had difficulty
negotiating stairs and rising from a seated position, and fatigues when speaking at length. Her birth and past
medical histories were otherwise unremarkable. There is no parental consanguinity or family history of muscle
disorders.
On examination, she had a BMI of 18 kg/m2, bilateral fatigable partial ptosis, complete external ophthalmoplegia
and fatigable proximal muscle weakness (MRC grade 4/5). Apart from spinal scoliosis the rest of the examination
was normal.
Haematological and biochemical investigations including serum lactate level and thyroid functions were normal.
Acetylcholine receptor antibodies and muscle specific kinase antibodies were not detected in serum. Repetitive
nerve stimulation showed marked decrement (>30 %) in nerve-muscle pairs in the face and forearm. Her DNA
sequencing revealed a c.183-187dupCTCAC mutation in CHRNE.
She remained functionally independent on pyridostigmine treatment.
Conclusions: This case describes a rare mutation of the CHRNE gene in CMS and highlights the relevance of
genetic diagnosis in CMS. It further adds to map the occurrence of such mutations in Asian populations.
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Background
Congenital myasthenic syndromes (CMSs) are a heteroge-
neous group of genetically determined neuromuscular
transmission disorders characterized by fatigable muscle
weakness that usually manifest early in life. Genetic muta-
tions alter structural and functional proteins at the motor
endplate leading to impaired neuromuscular transmission.
To date, at least 22 CMS-associated disease genes have
been identified, of which acetylcholine receptor deficiency
due to ε subunit (CHRNE) gene mutations have been found
to be the commonest [1–3]. However, CMSs are rare and
the mutation c.183_187dupCTCAC in CHRNE has been
previously reported only once [4]. We identified this muta-
tion in a South Asian individual affected with CMS.
Case presentation
A 17-year-old Maldivian female domiciled in Sri Lanka
presented with bilateral partial ptosis, fatigable proximal
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muscle weakness and slurring of speech noted since the
age of 2 years. She recalls having difficulty in swallowing
and being unable to run and play with her friends during
her childhood and as she was growing up, requiring as-
sistance to perform normal physical activities which her
friends were able to do with ease, such as negotiating
stairs. She particularly recalls being easily fatigued. She
had been diagnosed with early childhood ‘autoimmune
myasthenia gravis’ at the age of 4 years and commenced
on pyridostigmine, which she had increased by herself
over the years to her current regimen of 60 mg, five
times a day as she had been experiencing greater fatigue
with less frequent dosing. Her mother was uncertain of
any definitive tests done, including acetylcholine recep-
tor antibody status. The pyridostigmine provides her
with symptomatic benefit but not completely, hence
restricting her from activities that require rigorous effort.
She cannot run, has difficulty negotiating stairs and ris-
ing from a seated position, and fatigues if she continues
to speak at length. At times, particularly after a physic-
ally exhaustive day, she would experience blurring of
vision and dysphagia, while even smiling would take
much effort. Inter-current illnesses worsen her disabil-
ities making her bed-bound and often requiring hos-
pitalisation for specific and supportive treatment.
Furthermore, she recalls that she takes longer than her
friends to recover from similar illnesses. However, she has
adapted within her limitations and remains independent
in activities of daily living and has been able to continue
with her aspired educational pathway, currently studying
for a degree in forensic psychology. Her birth and past
medical histories were otherwise unremarkable. There is
no parental consanguinity or family history of muscle dis-
orders (Fig. 1a).
On examination, she had a BMI of 18 kg/m2, bilateral
fatigable partial ptosis, complete external ophthalmople-
gia and fatigable proximal muscle weakness (MRC grade
4/5). Deep tendon reflexes were normal and there were
no sensory deficits. Apart from spinal scoliosis, other
systems examination was normal.
Haematological and biochemical investigations includ-
ing full blood count, inflammatory markers, glucose,
renal and liver function tests were normal. Serum lactate
level was normal. Thyroid functions were within normal
limits. Acetylcholine receptor antibodies and muscle spe-
cific kinase antibodies were not detected in serum. A dec-
rement of >30 % was noted on repetitive nerve stimulation
of facial nerves (right 2.61 to 1.39 mV and left 2.57 to
1.64 mV) and of radial nerves (right 0.55 to 0.36 mV and
left 0.40 to 0.27 mV), which were done at the age of
17 years. Her DNA sequencing revealed an apparent
duplication of nucleotide residues 183–187 within exon 2
of the AChR epsilon (ε) subunit gene (c.183_187dupCT-
CAC) (Fig. 1b).
Conclusions
Genetic mutations responsible for CMSs have been iden-
tified in relation to proteins in the presynaptic, synaptic
and postsynaptic compartments of the neuromuscular
endplate. As expected, the frequency of particular gene
mutations varies within different ethnic groups, but in
most populations the most common form of CMS is due
to a deficiency of acetylcholine receptors on the postsynap-
tic membrane [3]. These can result from recessive mis-
sense, nonsense, frameshift or splice site and promoter
region mutations in any of the genes encoding the acetyl-
choline receptor subunits. However, a high frequency of
mutations in the acetylcholine receptor ε subunit (CHRNE)
compared with other subunits has been recognised and at-
tributed to the phenotypic rescue by maintained low level
expression of the foetal γ subunit that substitutes for the
b
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Fig. 1 a Family tree of patient. Her paternal grandfather had died of
malignancy. Arrow indicates proband. b Sequencing traces from a
region within exon 2 of the CHRNE gene from a healthy individual
and the patient. The 5-nucleotide insertion c.127insCTCAC is indicated
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defective ε subunit, but cannot compensate for the other
muscle acetylcholine receptor subunits. Our patient was di-
agnosed with c.183_187dupCTCAC within CHRNE, which
is predicted to convert Leu–Asn–Glu codons to Pro–His–
Stop at positions 63–65 of the protein p.(Leu63fs), resulting
in truncation of the ε subunit in its extracellular domain
[4]. This variant is SNP rs776927709, whose allele fre-
quency count of 1.64728e-05 is low enough to be the cause
of a rare recessively inherited genetic disease such as CMS.
From the sequencing data presented here, this duplication
is predicted to be homozygous. Sequence analysis of the
parental DNA would provide confirmation but unfortu-
nately parental DNA was not available. Therefore a hetero-
zygous deletion with concomitant removal of one or both
primer binding sites, which would produce the same chro-
matogram, cannot be excluded. Although our patient dem-
onstrated the typical phenotype of CHRNE mutation CMS,
a genetic diagnosis was confirmed only 15 years after onset,
and a previous diagnosis of ‘autoimmune myasthenia
gravis’ was revised precluding the risk of inadvertent im-
munotherapy. Furthermore, specific genetic diagnosis pro-
vided the option of adding 3,4 diaminopyridine and
salbutamol when symptomatically required [2, 5].
In a review of patients attending a comprehensive
neuromuscular clinic in India over a period of 8 years,
4.8 % of 314 myasthenic individuals were found to have
CMS, but a genetic diagnosis had not been ascertained
in them [6]. However, interestingly, certain founder mu-
tations of CMS have been identified in individuals of In-
dian subcontinent origin [7, 8]. There was no family
history of neuromuscular disorders in our patient, but
unavailability of DNA from her parents precluded fur-
ther evaluation of the origins of the identified mutation.
CMS can be clinically diagnosed on the basis of onset
at birth to early childhood, fatigable weakness particu-
larly of oculo-cranial muscles, a positive family history,
and a decremental response on repetitive nerve stimula-
tion. However, some patients may present later in life or
the distribution of weakness may not be typical and a
decremental response may not be easily evident, making
differentiation from other neuromuscular disorders difficult.
Some patients are mistakenly diagnosed with autoimmune
myasthenia gravis mediated by antibodies against acetylcho-
line receptors or muscle specific tyrosine kinase, which are
known to occur worldwide including in South Asia [9, 10],
leading to inappropriate treatment with immunosuppressive
drugs. Furthermore, drugs with mechanisms countering
specific neuromuscular defects have been found to be ef-
fective in appropriate CMS subtypes, but harmful in other
CMS subtypes with molecular defects inverse to the drug
action [2]. Thus, a genetic diagnosis is important for diagno-
sis, treatment and prognostication of CMS.
Our case report adds to the number of CMS affected in-
dividuals identified with a rare mutation of the acetylcholine
receptor ε subunit gene and highlights the importance of
genetic diagnosis in CMS. It also highlights the occurrence
of such mutations among South Asian populations.
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